Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, pertussis, and poliomyelitis vaccine + influenza vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Repevax + Vaxigrip refers to the concomitant administration of two distinct vaccines developed by Sanofi Pasteur: Repevax (a Tdap-IPV booster) and Vaxigrip (a trivalent inactivated influenza vaccine). Repevax is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in individuals from 3 years of age, while Vaxigrip is used for the prevention of influenza. Clinical evaluation in older adults (60+ years) has confirmed that simultaneous administration at separate injection sites is safe and does not interfere with the immune response to either vaccine. Both products are biologics consisting of inactivated antigens or toxoids.
- Other names
- Repevax + VaxigripTdap-IPV + influenza vaccine
02
Targets
Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)FIM2/FIM3 (Fimbriae types 2 and 3)FHA (Filamentous hemagglutinin)PRN (Pertactin)TT (Tetanus toxoid)HA (Hemagglutinin)
Beyond the preview
Go deeper on diphtheria, tetanus, pertussis, and poliomyelitis vaccine + influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, pertussis, and poliomyelitis vaccine + influenza vaccine.